Marcos de Lima – VJRegenMed

Point-of-care CAR T-cells

admin_vjr_user — Thu, 08 Oct 2020 14:08:16 +0000

Marcos de Lima, MD, UH Cleveland Medical Center, Cleveland, OH, discusses the significance of point-of-care CAR T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Results of a site-manufactured anti-CD19 CAR-T in nHL

admin_vjr_user — Thu, 27 Aug 2020 10:06:55 +0000

Marcos de Lima, MD, of UH Cleveland Medical Center, Cleveland, OH, discusses the results of a study evaluating a second-generation anti-CD19 CAR-T construct consisting of a 4-1BB co-stimulatory domain in heavily pre-treated non-Hodgkin lymphoma (nHL) patients. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Outlook on the current CAR-T climate

admin_vjr_user — Thu, 27 Aug 2020 10:06:54 +0000

Marcos de Lima, MD, of UH Cleveland Medical Center, Cleveland, OH, provides an outlook on the current CAR T-cell climate including expanding the reach of therapies, determining the best model for manufacturing, and the goal of off-the-shelf therapies. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).